Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Appeal

NICE scrutiny letter to MSD : Scrutiny letter (PDF 38 KB)

NICE scrutiny letter to MSD : Scrutiny letter (PDF 102 KB)

BSR response to initial scrutiny letter : Response to scrutiny letter (PDF 237 KB)

MSD response to initial scrutiny letter : Response to scrutiny letter (PDF 50 KB)

NRAS response to initial scrutiny letter : Response to scrutiny letter (PDF 48 KB)

BSR Appeal letter : Appeal letter (PDF 433 KB)

MSD Appeal letter : Appeal letter (PDF 156 KB)

NRAS Appeal letter : Appeal letter (PDF 589 KB)

NICE final scrutiny letter to BSR : Final scrutiny letter (PDF 84 KB)

NICE final scrutiny letter to MSD : Final scrutiny letter (PDF 21 KB)

NICE scrutiny letter to BSR : Scrutiny letter (PDF 100 KB)

Appeal decision (PDF 391 KB)

Final appraisal determination information

Final appraisal determination document (PDF 668 KB)

Committee papers information

Committee papers (PDF 4.79 MB)

Appraisal consultation

Appraisal consultation document (PDF 818 KB)

Committee papers information

Committee papers (appendices 1-3) (PDF 10.87 MB)

Committee papers (appendices 4-11) (PDF 9.49 MB)

Committee papers (appendix 12) (PDF 10.14 MB)

Committee papers (appendices 13-19) (PDF 6.48 MB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report addendum information

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report addendum (PDF 391 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: appendix 1 updated assessment report (PDF 12.08 MB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: decision support unit report information

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: decision support unit report (PDF 1.56 MB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment group report information

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment group report (PDF 377 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report (PDF 9.51 MB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: institutes response to consultees and commentator comments on the draft scope and provisional matrix (replacement) (PDF 377 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final protocol (PDF 589 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final scope (PDF 55 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: equality impact assessment - scoping (PDF 15 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final scope (superseded) (PDF 94 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final matrix (PDF 34 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: provisional matrix (PDF 42 KB)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: draft scope (PDF 137 KB)